➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Colorcon
Boehringer Ingelheim
McKinsey
Merck

Last Updated: October 29, 2020

DrugPatentWatch Database Preview

Patent: 9,879,325

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,879,325
Title:Method for predicting the responsiveness a patient to a treatment with an anti-CD20 antibody
Abstract: The present invention relates to a method for predicting the responsiveness of a patient to a treatment with an anti-CD20 antibody, said method comprising measuring the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in B cells obtained from said patient.
Inventor(s): Chiche; Johanna (Nice, FR), Thieblemont; Catherine (Paris, FR), Ricci; Jean-Ehrland (Nice, FR)
Assignee: ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR) UNIVERSITE PARIS DIDEROT (PARIS VII) (Paris, FR) UNIVERSITE DE NICE--SOPHIA ANTIPOLIS (Nice, FR) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (Paris, FR)
Application Number:15/121,864
Patent Claims:see list of patent claims

Details for Patent 9,879,325

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR) UNIVERSITE PARIS DIDEROT (PARIS VII) (Paris, FR) UNIVERSITE DE NICE--SOPHIA ANTIPOLIS (Nice, FR) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (Paris, FR) 2034-03-03 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR) UNIVERSITE PARIS DIDEROT (PARIS VII) (Paris, FR) UNIVERSITE DE NICE--SOPHIA ANTIPOLIS (Nice, FR) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (Paris, FR) 2034-03-03 RX Orphan search
Genentech Inc OCREVUS ocrelizumab INJECTABLE;INJECTION 761053 001 2017-03-28   Start Trial ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR) UNIVERSITE PARIS DIDEROT (PARIS VII) (Paris, FR) UNIVERSITE DE NICE--SOPHIA ANTIPOLIS (Nice, FR) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (Paris, FR) 2034-03-03 RX search
Novartis KESIMPTA ofatumumab SOLUTION;SUBCUTANEOUS 125326 002 2009-10-26   Start Trial ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR) UNIVERSITE PARIS DIDEROT (PARIS VII) (Paris, FR) UNIVERSITE DE NICE--SOPHIA ANTIPOLIS (Nice, FR) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (Paris, FR) 2034-03-03 RX search
Novartis ARZERRA ofatumumab INJECTABLE; INJECTION 125326 001 2009-10-26   Start Trial ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR) UNIVERSITE PARIS DIDEROT (PARIS VII) (Paris, FR) UNIVERSITE DE NICE--SOPHIA ANTIPOLIS (Nice, FR) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (Paris, FR) 2034-03-03 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Dow
McKesson
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.